Literature DB >> 25432325

8-prenylnaringenin and tamoxifen inhibit the shedding of irradiated epithelial cells and increase the latency period of radiation-induced oral mucositis : cell culture and murine model.

Tine De Ryck1, Annouchka Van Impe, Barbara W Vanhoecke, Arne Heyerick, Luc Vakaet, Wilfried De Neve, Doreen Müller, Margret Schmidt, Wolfgang Dörr, Marc E Bracke.   

Abstract

PURPOSE: The major component in the pathogenesis of oral radiation-induced mucositis is progressive epithelial hypoplasia and eventual ulceration. Irradiation inhibits cell proliferation, while cell loss at the surface continues. We conceived to slow down this desquamation by increasing intercellular adhesion, regulated by the E-cadherin/catenin complex. We investigated if 8-prenylnaringenin (8-PN) or tamoxifen (TAM) decrease the shedding of irradiated human buccal epithelial cells in vitro and thus delay the ulcerative phase of radiation-induced mucositis in vivo.
MATERIALS AND METHODS: In vitro, aggregates of buccal epithelial cells were irradiated and cultured in suspension for 11 days. 8-PN or TAM were investigated regarding their effect on cell shedding. In vivo, the lower tongue surface of mice was irradiated with graded single doses of 25 kV X-rays. The incidence, latency, and duration of the resulting mucosal ulcerations were analyzed after topical treatment with 8-PN, TAM or solvent.
RESULTS: 8-PN or TAM prevented the volume reduction of the irradiated cell aggregates during the incubation period. This was the result of a higher residual cell number in the treated versus the untreated irradiated aggregates. In vivo, topical treatment with 8-PN or TAM significantly increased the latency of mucositis from 10.9 to 12.1 and 12.4 days respectively, while the ulcer incidence was unchanged.
CONCLUSION: 8-PN and TAM prevent volume reduction of irradiated cell aggregates in suspension culture. In the tongues of mice, these compounds increase the latency period. This suggests a role for these compounds for the amelioration of radiation-induced mucositis in the treatment of head and neck tumors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25432325     DOI: 10.1007/s00066-014-0782-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  32 in total

1.  Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa.

Authors:  Anja Gehrisch; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2007-01       Impact factor: 3.621

Review 2.  Radioprotection of normal tissue cells.

Authors:  Patrick Maier; Frederik Wenz; Carsten Herskind
Journal:  Strahlenther Onkol       Date:  2014-03-18       Impact factor: 3.621

Review 3.  Systematic review of amifostine for the management of oral mucositis in cancer patients.

Authors:  Ourania Nicolatou-Galitis; Triantafyllia Sarri; Joanne Bowen; Mario Di Palma; Vassilios E Kouloulias; Pasquale Niscola; Dorothea Riesenbeck; Monique Stokman; Wim Tissing; Eric Yeoh; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2012-10-03       Impact factor: 3.603

4.  Modification of oral mucositis by keratinocyte growth factor: single radiation exposure.

Authors:  W Dörr; R Noack; K Spekl; C L Farrell
Journal:  Int J Radiat Biol       Date:  2001-03       Impact factor: 2.694

5.  Radiation-induced changes in cellularity and proliferation in human oral mucosa.

Authors:  Wolfgang Dörr; Christopher S Hamilton; Teresa Boyd; Barry Reed; James W Denham
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

Review 6.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.

Authors:  Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg
Journal:  Radiother Oncol       Date:  2003-03       Impact factor: 6.280

7.  Characteristics of four new human cell lines derived from squamous cell carcinomas of the head and neck.

Authors:  H T Rupniak; C Rowlatt; E B Lane; J G Steele; L K Trejdosiewicz; B Laskiewicz; S Povey; B T Hill
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

8.  Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.

Authors:  Samy A F Morad; Jonathan C Levin; Su-Fern Tan; Todd E Fox; David J Feith; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2013-08-09

Review 9.  MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.

Authors:  Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad
Journal:  Cancer       Date:  2014-02-25       Impact factor: 6.860

10.  In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death.

Authors:  M L Hermiston; J I Gordon
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  3 in total

1.  Novel technique for high-precision stereotactic irradiation of mouse brains.

Authors:  J Hartmann; J Wölfelschneider; C Stache; R Buslei; A Derer; M Schwarz; T Bäuerle; R Fietkau; U S Gaipl; C Bert; A Hölsken; B Frey
Journal:  Strahlenther Onkol       Date:  2016-07-11       Impact factor: 3.621

Review 2.  The pathogenesis of mucositis: updated perspectives and emerging targets.

Authors:  J Bowen; N Al-Dasooqi; P Bossi; H Wardill; Y Van Sebille; A Al-Azri; E Bateman; M E Correa; J Raber-Durlacher; A Kandwal; B Mayo; R G Nair; A Stringer; K Ten Bohmer; D Thorpe; R V Lalla; S Sonis; K Cheng; S Elad
Journal:  Support Care Cancer       Date:  2019-07-08       Impact factor: 3.603

Review 3.  The Potent Phytoestrogen 8-Prenylnaringenin: A Friend or a Foe?

Authors:  Raimo Pohjanvirta; Atefeh Nasri
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.